Evidence
Aliment Pharmacol Ther. 2024 May;59(10):1294-1295. doi: 10.1111/apt.17992.
NO ABSTRACT
PMID:38652769 | DOI:10.1111/apt.17992
Estimated reading time: 1 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Editorial: Crystalising the burden of steatotic liver disease-Authors’ reply
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- Psychedelics in treatment of postraumatic stress disorder
- Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
- Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies
- MDMA-assisted therapy for PTSD
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China
- Reply to: Frailty and ethics at the end of life: The importance of a comprehensive assessment
- New nomenclature for fatty liver disease
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- A novel dual near-infrared fluorescent probe for bioimaging and visualization of viscosity in acute alcoholic liver injury
- Erythropoietin hyporesponsiveness in non-alcoholic fatty liver disease
- Spatial genomics: mapping human steatotic liver disease
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis
- Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of…
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Changes in the etiology of liver cirrhosis and the corresponding management strategies
- COVID-19 in Individuals with Chronic Liver Diseases
- Long-term risk of cardiovascular disease associated with MASLD and different cardiometabolic risk factors in IBD patients: A prospective cohort study
- Long-term risk of cardiovascular disease associated with MASLD and different cardiometabolic risk factors in IBD patients: A prospective cohort study
- Obituary: Travis Thompson-Editorial
- Association between the skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease: A cross-sectional study of NHANES 2017-2018
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Home monitoring to detect progression of interstitial lung disease: A prospective cohort study
- A child with Kawasaki disease and acute pancreatitis: Atypical presentation
- Editorial: "What say you?" The promise and potential pitfalls of using automated and passive monitoring approaches to assess parenting behaviours from verbal and written communication
- Editorial: "What say you?" The promise and potential pitfalls of using automated and passive monitoring approaches to assess parenting behaviours from verbal and written communication
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective
- RETRACTION: Reduced self-harm on acute mental health wards following the implementation of a vision-based patient monitoring system: Evidence from five NHS trusts
- Editorial: Management of PJI/SSI after joint arthroplasty
- Editorial: Management of PJI/SSI after joint arthroplasty
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
- Silibinin, a commonly used therapeutic agent for non-alcohol fatty liver disease, functions through upregulating intestinal expression of fibroblast growth factor 15/19
- An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
- Gestational diabetes mellitus may predispose to metabolic dysfunction-associated steatotic liver disease
- Editorial on common mental health disorders and cognitive decline in a longitudinal Down syndrome cohort
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- Immune signature and therapeutic approach of natural killer cell in chronic liver disease and hepatocellular carcinoma
- Single nucleotide polymorphisms in the cannabinoid CB2 receptor: Molecular pharmacology and disease associations
- Editorial perspective: Transforming child and adolescent mental health services and systems (CAMHSS) around the globe - the importance of diversity, inclusion and equity in CAMHSS research
- An aggressive mediastinal EBV-associated large B cell lymphoma
- [Retracted] MicroRNA‑584 prohibits hepatocellular carcinoma cell proliferation and invasion by directly targeting BDNF
- Hedan tablet ameliorated non-alcoholic steatohepatitis by moderating NF-kappaB and lipid metabolism-related pathways via regulating hepatic metabolites
- The gut-liver axis in fatty liver disease: role played by natural products
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- When I say … active learning
- When I say … inclusive teaching
- Para-fluorofentanyl: Coincidence or intentional?
- Obituary: Kypros Kypri
- Response letter: Complexities in pericyte markers
- An update of contemporary insulin therapy
- Clinical features of individuals with laboratory values suggestive of advanced liver fibrosis when first treated for alcohol use disorder
- Collaborative research for psychosis prediction and prevention
- Ethical concerns related to the use of artificial intelligence in dermatopathology
Evidence Blueprint
Editorial: Crystalising the burden of steatotic liver disease-Authors’ reply
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Editorial: Crystalising the burden of steatotic liver disease-Authors’ reply
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- Psychedelics in treatment of postraumatic stress disorder
- Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
- The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysis
- Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies
- Review article: Current indications and selection criteria for early liver transplantation in severe alcohol-associated hepatitis
- Systematic review and meta-analysis: Association between liver fibrosis and subclinical atherosclerosis in nonalcoholic fatty liver disease
- Meta-analysis: Impact of intragastric balloon therapy on NAFLD-related parameters in patients with obesity
- Epidemiology and risk factors for histopathologic characteristics of non-alcoholic fatty liver disease in South America
- The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma
- Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction-associated steatotic liver disease - The Gut and Obesity in Asia (GO-ASIA) Study
- Meta-analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non-alcoholic steatohepatitis and non-alcoholic steatohepatitis-related fibrosis
- MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease
- Systematic review: Glycomics as diagnostic markers for hepatocellular carcinoma
- Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
- Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial
- First in human randomised trial of J2H-1702: A novel 11β-hydroxysteroid dehydrogenase type 1 inhibitor for non-alcoholic steatohepatitis treatment
- MDMA-assisted therapy for PTSD
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- Steatotic hepatocyte-derived extracellular vesicles promote β-cell apoptosis and diabetes via microRNA-126a-3p
- Potential Mechanisms Involving in the Pathogenesis of MASLD and Targets for Pharmacotherapy. Advancements in Metabolic Associated Steatotic Liver Disease (MASLD) Research: Diagnostics, Small Molecule Developments and Future Directions
- Commentary: The evidence base regarding the long-term effects of childhood mental disorder treatments needs to be strengthened - reply to Dekkers et al. (2023)
- Letter regarding 'Association of thyroid function with non-alcoholic fatty liver disease in recent-onset diabetes'
- Relationship of ferritin and hepcidin with disease severity in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus
- Reply to: Disease latency and new-user versus prevalent-user cohort designs: Implications for pharmacoepidemiology in dementia
- Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China
- The double roles of T cell-mediated immune response in the progression of MASLD
- Reply to: Comment on: Association of sulfonylureas with the risk of dementia: A population-based cohort study
- Reply to: Frailty and ethics at the end of life: The importance of a comprehensive assessment
- MBOAT7 in liver and extrahepatic diseases
- Liver disease mortality and hospitalisations among people with type 2 diabetes mellitus: A population-based study
- New nomenclature for fatty liver disease
- Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: A cross-sectional study
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- The significance of omega-3 fatty acids in the treatment of non-alcoholic fatty liver disease
- Reply to Ng: a closer look at late-onset psychoses for the general internist
- The promise of N-acetylcysteine in the treatment of obsessive-compulsive disorder
- From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
- Therapeutic management of metabolic dysfunction associated steatotic liver disease
- Pharmacogenetic testing of CYP2D6, CYP2C19 and CYP2C9 in Denmark: Agreement between publicly funded genotyping tests and the subsequent phenotype classification
- Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
- Reply to: Positive aspects of caregiving attenuate the relationship between behavioral bother and anxiety and depressive symptoms in dementia family caregivers. Geriatr. Gerontol. Int. 2023;1. https://doi.org/10.1111/ggi.1460
- Exclusive liquor and cocktail consumption is associated with at-risk fibrosis among nonheavy alcohol users with metabolic dysfunction-associated steatotic liver disease
- Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- A novel dual near-infrared fluorescent probe for bioimaging and visualization of viscosity in acute alcoholic liver injury
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
- Erythropoietin hyporesponsiveness in non-alcoholic fatty liver disease
- Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
- Editorial: Prevention is the best cure - or is it? A cautionary tale
- Non-alcoholic fatty liver disease, women's health and the role of the environment
- Spatial genomics: mapping human steatotic liver disease
- Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis
- Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of…
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults
- Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
- Plastic compounds and liver diseases: Whether bisphenol A is the only culprit